Safeguarding Women from Chemical Abortion Act
Sponsored By: Senator Josh Hawley
Introduced
Summary
Withdraw federal approval for mifepristone used to terminate intrauterine pregnancy. The bill would also create a federal private right of action so people harmed by that drug can sue manufacturers.
Show full summary
- Women and families: Would limit the legal use and interstate availability of mifepristone for termination of intrauterine pregnancy by deeming those approvals withdrawn 14 days after enactment and treating introduction into interstate commerce as unlawful.
- Manufacturers: Would expose makers of the approved mifepristone to federal liability for bodily injury or mental harm linked to the drug and allow suits for compensatory and punitive damages and attorney fees in federal or state court, with the remedy effective 90 days after enactment.
- Labeling and market rules: Would deem mifepristone misbranded if labeling says it may be used for termination of intrauterine pregnancy or with another drug for that purpose, and would bar interstate commerce of products whose approval has been withdrawn.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Remove federal approval for mifepristone
If enacted, this bill would treat FDA approvals for mifepristone (Mifeprex, RU-486) for ending intrauterine pregnancy as withdrawn 14 days after enactment. It would also treat selling or shipping such withdrawn products across state lines as a violation of the Federal Food, Drug, and Cosmetic Act. Labels saying the drug can be used to end pregnancy or with another drug for that purpose would be deemed misbranded. If enacted, patients could lose nearby access to the drug, face travel or higher out-of-pocket costs, or need other procedures.
New right to sue mifepristone makers
If enacted, this bill would create a federal private right of action for individuals who suffer bodily injury or mental-health harm tied to use of mifepristone approved for ending intrauterine pregnancy. A person harmed could sue the manufacturer in federal or state court for compensatory and punitive damages, and recover attorney fees and costs. This new cause of action would take effect 90 days after enactment.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Josh Hawley
MO • R
Cosponsors
John Cornyn
TX • R
Sponsored 3/12/2026
Marsha Blackburn
TN • R
Sponsored 3/18/2026
Ted Budd
NC • R
Sponsored 3/23/2026
Tommy Tuberville
AL • R
Sponsored 3/25/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in